Nuvaxovid
COVID has significantly disrupted life across the entire world these past two years. Although not without risks and controversy, vaccines have been a significant tool used by public health agencies to protect both their citizens and critical health infrastructure. To date, more than 90% of adult Canadians are fully vaccinated compared to less than55% globally. According to our government website, Canada has committed to donating the equivalent of at least 200 million doses to the COVAX Facility by the end of 2022 but, as of February 11, 2022, only 13.3 million surplus vaccine doses have actually been delivered.
Novavax’s Nuvaxovid was approved for use in Canada just this week (on February 17, 2022) and is reported to be effective against the Omicron variant. It is a protein-based vaccine but not an mRNA. The main difference between Novavax and mRNA vaccines is that it is made with lab-grown copies of the COVID-19 spike protein, whereas mRNA vaccines include genetic instructions for the body to make its own spike protein. No rare but dangerous side effects other than anaphylaxis have been identified.
BYOP and TOTT
CONGRATULATIONS to Nighthawk54 for FTF!